VIA
CMPX icon

Virtus Investment Advisers’s Compass Therapeutics CMPX Stock Holding History

Virtus Investment Advisers’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Buy
161,181
+108,335
+205% +$320K 0.08% 346
2026
Q1 		$280K Buy
52,846
+1,290
+3% +$7.45K 0.08% 293
2025
Q4 		$277K Buy
+51,556
New +$238K 0.08% 275

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Virtus Investment Advisers's CMPX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Compass Therapeutics (CMPX) stake by 205% in Q2 2026, buying an estimated $320K and bringing the position to 161,181 shares worth $353K. The position accounts for 0.08% of the portfolio, ranked #346.

Virtus Investment Advisers first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Virtus Investment Advisers held 161,181 shares of Compass Therapeutics worth $353K as of Q2 2026.
  • Virtus Investment Advisers bought 108,335 Compass Therapeutics shares in Q2 2026, an estimated $320K.
  • Compass Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #346 holding.
  • Virtus Investment Advisers first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.